A detailed history of Vanguard Group Inc transactions in Greenwich Life Sciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 273,525 shares of GLSI stock, worth $3.39 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
273,525
Previous 268,168 2.0%
Holding current value
$3.39 Million
Previous $4.63 Million 15.08%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$12.99 - $17.58 $69,587 - $94,176
5,357 Added 2.0%
273,525 $3.93 Million
Q2 2024

Aug 13, 2024

BUY
$12.07 - $19.04 $543,946 - $858,056
45,066 Added 20.2%
268,168 $4.63 Million
Q1 2024

May 10, 2024

BUY
$8.31 - $20.32 $11,800 - $28,854
1,420 Added 0.64%
223,102 $4.45 Million
Q4 2023

Feb 14, 2024

BUY
$7.77 - $12.3 $13,434 - $21,266
1,729 Added 0.79%
221,682 $2.33 Million
Q3 2023

Nov 14, 2023

SELL
$8.41 - $10.66 $523,623 - $663,712
-62,262 Reduced 22.06%
219,953 $1.94 Million
Q2 2023

Aug 14, 2023

SELL
$9.58 - $13.2 $671,644 - $925,438
-70,109 Reduced 19.9%
282,215 $2.72 Million
Q1 2023

May 15, 2023

BUY
$12.12 - $20.8 $94,536 - $162,240
7,800 Added 2.26%
352,324 $4.86 Million
Q4 2022

Feb 10, 2023

BUY
$9.04 - $16.88 $795 - $1,485
88 Added 0.03%
344,524 $5.24 Million
Q3 2022

Nov 14, 2022

SELL
$7.81 - $12.02 $76,538 - $117,796
-9,800 Reduced 2.77%
344,436 $3.13 Million
Q2 2022

Aug 12, 2022

SELL
$7.14 - $20.36 $149,682 - $426,827
-20,964 Reduced 5.59%
354,236 $3 Million
Q1 2022

May 13, 2022

BUY
$16.3 - $24.65 $3.67 Million - $5.55 Million
225,213 Added 150.16%
375,200 $7.36 Million
Q4 2021

Feb 14, 2022

BUY
$21.76 - $39.43 $15,079 - $27,324
693 Added 0.46%
149,987 $3.65 Million
Q3 2021

Nov 12, 2021

BUY
$38.65 - $46.11 $1.08 Million - $1.29 Million
27,876 Added 22.96%
149,294 $5.83 Million
Q2 2021

Aug 13, 2021

BUY
$31.24 - $53.6 $3.79 Million - $6.51 Million
121,418 New
121,418 $5.46 Million

Others Institutions Holding GLSI

About Greenwich LifeSciences, Inc.


  • Ticker GLSI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,848,200
  • Market Cap $159M
  • Description
  • Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who ha...
More about GLSI
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.